← Back to Search

N/A

Tumor biopsy for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant is a candidate for molecular screening for a GlaxoSmithKline (GSK) precision therapeutic clinical study (the Intended Treatment Protocol) that is being conducted in parallel at or nearby the MDCI recruitment site.
Participant is willing to travel to a site recruiting for the intended GSK treatment protocol (or alternative treatment protocol), if feasible, and if, in the investigator's opinion, the participant would benefit from enrolment into the intended GSK treatment protocol at an alternative clinical site.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial will collect tumor tissue and blood samples from people with advanced cancer to study the disease at a molecular level.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Tumors

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with positive Inducible T-cell Co-Stimulator (ICOS) status
Squamous cell carcinoma of esophagus
Number of participants with positive Programmed death protein 1 Ligand (PD-L1) status

Side effects data

From 2009 Phase 2 trial • 19 Patients • NCT00244933
26%
White blood cells (WBC)
26%
Absolute neutrophil count (ANC)
16%
Pain
16%
Dyspnea
16%
Platelets
11%
Fatigue
5%
Elevated Alanine Aminotransferase (ALT)
5%
Elevated Aspartate Aminotransferase (AST)
5%
Hemoglobin (Hgb)
5%
Vomiting
5%
Rash
5%
Elevated Alkaline Phosphate
5%
Hot flashes
100%
80%
60%
40%
20%
0%
Study treatment Arm
Gemcitabine & Genistein

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants undergoing tumor biopsyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tumor biopsy
2014
Completed Phase 2
~240

Find a Location

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor
4,742 Previous Clinical Trials
8,066,355 Total Patients Enrolled
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,593 Previous Clinical Trials
6,143,347 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is it risky to have a Tumor biopsy?

"While there is some data supporting the safety of a tumor biopsy, as this is only a phase 2 trial, none of the available information suggests that the procedure is effective."

Answered by AI

Are there any available positions for participants in this trial?

"The clinicaltrials.gov website indicates that this trial is currently looking for patients to enroll. The study was originally posted on May 25th, 2021 and was updated as recently as August 11th, 2022."

Answered by AI

How many individuals are being recruited for this research project?

"The listing on clinicaltrials.gov indeed suggests that this study is still enrolling patients. The trial was first advertised on May 25th, 2021 and edited as recently as August 11th, 2022. They are looking for 400 people to participate at 1 location."

Answered by AI
~2 spots leftby Mar 2025